New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. [electronic resource]
Producer: 20160810Description: 28774-89 p. digitalISSN:- 1949-2553
- Anaplastic Lymphoma Kinase
- Animals
- Antineoplastic Agents -- pharmacokinetics
- Biological Availability
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Female
- Gene Expression Regulation, Enzymologic -- drug effects
- Gene Expression Regulation, Neoplastic -- drug effects
- Half-Life
- Humans
- Liposomes
- Male
- Mice, Inbred BALB C
- Mice, Nude
- Molecular Targeted Therapy
- Mutation
- Nanoparticles
- Neuroblastoma -- enzymology
- Protein Kinase Inhibitors -- pharmacokinetics
- RNA Interference
- RNA, Small Interfering -- genetics
- RNAi Therapeutics
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Transfection
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.